Type 2 diabetes and obesity are rapidly increasing worldwide, posing substantial clinical and healthcare system burdens. 1 The coexistence of obesity and type 2 diabetes poses a major clinical and public health challenge, as their synergistic effects amplify metabolic dysfunction and cardiometabolic risk. Glycaemia-centric strategies alone are insufficient to address the shared pathophysiology driven by excess adiposity and insulin resistance. 2 This convergence underscores the urgent need for therapies that address both dysglycaemia and excess adiposity in an integrated manner.
Semaglutide, a glucagon-like peptide-1 receptor agonist has transitioned from a novel therapeutic concept to a cornerstone of contemporary metabolic management. Its role reflects a paradigm shift toward weight-centric strategies in diabetes care. 1 Join us for a high-impact clinical webinar on 27th January 2026…
